Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?

Pharmacotherapy - 1 Jun 2008

Perera Minoli A, Innocenti Federico, Ratain Mark J

Abstract excerpt

Recent changes to the labels of three prescription drugs--irinotecan, 6-mercaptopurine, and warfarin--include recommendations for pharmacogenetic testing in patients. Thus, clinicians are faced with determining the utility and practicality of pharmacogenetic testing in clinical practice. We illus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Genotype
Share to Glucuronosyltransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Irinotecan

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Share to Protease Inhibitors

Source

Identifiers

PMID: 18503403
DOI: 10.1592/phco.28.6.755

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18503403-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?PMID 18503403Read ↗

Pharmacogenetic approach for cancer treatment-tailored medicine in practice.Semantic proximity Read ↗

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.Semantic proximity Read ↗

TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?Semantic proximity Read ↗

Pharmacogenetics and irinotecan therapy.Semantic proximity Read ↗

Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.Semantic proximity Read ↗

The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions.Semantic proximity Read ↗

UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?Semantic proximity Read ↗

Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.Semantic proximity Read ↗

An overview of the recent progress in irinotecan pharmacogenetics.Semantic proximity Read ↗

Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapySemantic proximity Read ↗

Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.Semantic proximity Read ↗

Precision Medicine: UGT1A1 Genotyping to Better Manage Irinotecan-Induced Toxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.